Senores Pharmaceuticals has scheduled a group meeting with analysts and institutional investors on July 7, 2026, at its corporate office in Ahmedabad, Gujarat. The interaction is set to commence at 10:00 A.M. IST and will be conducted in physical mode. The purpose of the meeting is to engage with market participants and discuss the company's performance based on publicly available data.

The company explicitly stated that no unpublished price sensitive information (UPSI) is intended to be shared during these interactions. This disclosure ensures compliance with regulatory norms regarding fair disclosure and transparency. The meeting provides an opportunity for investors to gain direct insights from the company's management regarding its operations and financial health.

The following table outlines the schedule for the meeting:

Senores Pharmaceuticals noted that the schedule is subject to change due to unforeseen exigencies on the part of the host or the company. Participants are advised to take note of this possibility. The intimation was formally submitted to the stock exchanges pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The meeting will be attended by company officials, including senior management, to address queries from the analyst and investor community. This engagement is part of the company's regular investor relations activities to maintain open lines of communication with the market.

Senores Pharmaceuticals Limited relieved Company Secretary Vinay Kumar Mishra from his duties effective the close of business hours on June 10, 2026. The company informed the stock exchanges that the relief follows his earlier resignation intimation dated May 14, 2026.

In accordance with Regulation 30(5) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has designated specific Key Managerial Personnel (KMP) to determine the materiality of events and information for disclosures to the exchanges.

The authorized personnel include Managing Director Mr. Swapnil Jatinbhai Shah and Whole Time Director and Chief Financial Officer Mr. Deval Rajnikant Shah. The contact details for the Managing Director have been provided to facilitate necessary communications.

The company confirmed that the requisite information, including the copy of the resignation letter, was previously submitted to the exchanges as per SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Authorized Key Managerial Personnel